UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Report: 'Pharmacy Benefit Managers' profited billions by raising prices of 'specialty drugs'
The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
UnitedHealth Group CEO says complex US healthcare system needs to change
UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector ...
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
REVEALED: UnitedHealth overcharges cancer patients by 1,000%... as it sees surprise profit after CEO murdered
UnitedHealth Group (UHG) has been overcharging some cancer patients by more than 1,000 percent for live-changing drugs, a ...
Lawmaker may file bill to regulate PBMs: They’re managing the dollar
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
FTC report finds pharmacy benefit managers hiked prices of generic drugs
A new report by the Federal Trade Commission says pharmacy benefit management companies are driving up your out-of-pocket costs for prescription drugs.
UnitedHealth fights back: Blame drugmakers for high costs, not the 'middlemen.'
On the post-earnings call with analysts, Chief Executive Andrew Witty addressed the recent public backlash over high drug costs and transparency of coverage, particularly following killing of Brian ...